Pick Your Community: | Hopkins | Muhlenberg | Daviess | Christian | Fayette | Henderson | Lakes | McCracken | Warren | Webster

FDA Approves New Drug for Advanced Prostate Cancer

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2014 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story by using one of the social media links below.

In Other News...

Dont Miss Out on a Howl of a Good Time

OWENSBORO, Ky. (7/28/14) — The Owensboro Parks and Recreation Department will be hosting the 9th annual 'Gone to the… Read More

ODC 14-Year-Olds Compile 2-1 Record in Pool Play

HENDERSON, Ky. (7/28/14) — The Owensboro-Daviess County 14-year-old All-Stars notched a 2-1 record in pool play of the… Read More

Most Read This Week (Site-Wide)

July 24, 2014 3855

Powderly Man Injured in Apparent Gun…

in Top Stories by Charles W. Riley II, SurfKY News
July 24, 2014 2766

Madisonville Man Charged for Drugs,…

in Top Stories by Trooper Stu Recke
July 25, 2014 2151

No One Injured in Truck-Train Collision

in Top Stories by Ami Clayton, SurfKY News
July 24, 2014 1764

Muhlenberg to Have State's Only Honey…

in Top Stories by Charles W. Riley II, SurfKY News
July 25, 2014 1416

Vehicle Strikes Lawn Mower Driven on…

in Top Stories by Dep. Mike Evans

Most Read Stories from Hopkins County

July 24, 2014 2766

Madisonville Man Charged for Drugs,…

in Top Stories by Trooper Stu Recke
July 25, 2014 2151

No One Injured in Truck-Train Collision

in Top Stories by Ami Clayton, SurfKY News
July 25, 2014 1416

Vehicle Strikes Lawn Mower Driven on…

in Top Stories by Dep. Mike Evans
July 28, 2014 1085

Two Injured in Vehicle Collision on…

in Top Stories by William Roundtree
July 24, 2014 1073

Hopkins County Fair Provides Family Fun

in Top Stories by Ami Clayton, SurfKY News

Most Read Stories from Owensboro

July 24, 2014 1331

US 231 Ohio River 'William Natcher'…

in News by Keith Todd
July 24, 2014 1031

Maintenance Scheduled at Fisher Park and…

in News by Brittni Bunn
July 24, 2014 879

Portion of Spring Bank Drive Closed…

in News by Sherry Girten
July 28, 2014 493

Dont Miss Out on a Howl of a Good Time

in News by Brittni Bunn
July 24, 2014 289

Owensboro Southern 11-Year-Olds Finish…

in Top Stories by Steve LeMaster

Most Read Stories from Muhlenberg County

July 24, 2014 3855

Powderly Man Injured in Apparent Gun…

in Top Stories by Charles W. Riley II, SurfKY News
July 24, 2014 1764

Muhlenberg to Have State's Only Honey…

in Top Stories by Charles W. Riley II, SurfKY News
July 24, 2014 1293

Marching Mustangs Band Camp Underway

in Top Stories by Charles W. Riley II, SurfKY News
July 25, 2014 1240

Business Spotlight - McQuady's Automotive

in Top Stories by Charles W. Riley II, SurfKY News
July 25, 2014 1092

Business Spotlight - Blue Moon Car Wash

in Top Stories by Charles W. Riley II, SurfKY News

SurfKY News Group, Inc. Central Office & Printing Division
1125 Nebo Rd.  •  Madisonville, KY 42431  •  270.452.2249 (fax)
Main Number: 270.452.2727 (phone)  •  Printing Division Direct Line: 270.821.8600 (phone)

SurfKY Owensboro News Bureau
920 Frederica St. / Suite 210  •  Owensboro, KY 42301  •  270.683-8060 (phone)


Contact a member of our staff: www.surfky.com/contact
Copyright © 2014 SurfKY News Group, Inc.  •  Terms of Use  •  Site Map

social 06social 21social 22social 04social 03